Home Cart Sign in  
Chemical Structure| 124083-20-1 Chemical Structure| 124083-20-1

Structure of Etomoxir
CAS No.: 124083-20-1

Chemical Structure| 124083-20-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Etomoxir is a cell-permeable, irreversible, and stereospecific inhibitor of carnitine palmitoyltransferase (CPT)-1 and DGAT activity in the mitochondria of rat heart H9c2 myoblastic cells at a concentration of 1-80 μM and 40 μM, respectively.

Synonyms: (R)-(+)-Etomoxir

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Etomoxir

CAS No. :124083-20-1
Formula : C17H23ClO4
M.W : 326.82
SMILES Code : O=C([C@]1(CCCCCCOC2=CC=C(Cl)C=C2)OC1)OCC
Synonyms :
(R)-(+)-Etomoxir
MDL No. :MFCD11227266
InChI Key :DZLOHEOHWICNIL-QGZVFWFLSA-N
Pubchem ID :9840324

Safety of Etomoxir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCTR cells 100 μM 7 days To evaluate the effect of Etomoxir on the clone formation capacity of HCTR cells, the results showed that Etomoxir significantly reduced the clone formation of HCTR cells. PMC10646284
RAW264.7 cells 25 μM 24 h Inhibition of CPT1 significantly increased the secretion of 12/15-LOX-derived oxylipins PMC8748967
peritoneal macrophages 25 μM 24 h Etomoxir significantly increased the detected levels of several monohydroxy lipids and COX-2 products PMC8748967
brown adipocytes 10 µM 15 min To test the effect of Etomoxir on the respiratory capacity of brown adipocytes, it was found that Etomoxir treatment significantly reduced oxygen consumption, indicating that fatty acid oxidation plays an important role in respiratory capacity. PMC7476754
HeLa-LNM2 cells 100 μM Inhibited CPT1A activity, reduced ATP levels and maximum respiration rate PMC11151054
SiHa-LNM2 cells 100 μM Inhibited CPT1A activity, reduced ATP levels and maximum respiration rate PMC11151054
OT-I TRM cells 40 μM 15 min Inhibited mitochondrial fatty acid β-oxidation, preventing the increase in OCR of OT-I TRM cells PMC5509051
Jurkat cells 20 μM 24 h To test the effect of Etomoxir on the metabolism of Jurkat cells, results showed that Etomoxir significantly increased the level of propionyl-carnitine and decreased the level of butyryl-carnitine. PMC9996616
BSC40 cells 360 µM 16 h To investigate the effect of Etomoxir on viral yield, results showed that Etomoxir significantly inhibited viral yield, and the inhibition was more pronounced in the absence of exogenous glucose. PMC3961357
BMDM 4 μM 18 h To test the effect of Etomoxir on fatty acid oxidation and oxidative phosphorylation in BMDM cells, results showed that Etomoxir treatment significantly reduced OCR, indicating inhibition of CPT1A-dependent fatty acid oxidation. PMC10436255
pDCs 200 μM 24 h Etomoxir inhibited the CpGA-induced increase in basal OCR and SRC in pDCs, indicating that CpGA stimulation of pDCs results in enhanced OXPHOS largely due to increased FAO. PMC5695232

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB-17 SCID mice HCT116 and HCTR xenograft models intraperitoneal injection 30 mg/kg Days 12, 13, 14, 15, 18, 19, 20, 21 To evaluate the effect of Etomoxir on the volume of HCTR xenograft tumors, the results showed that Etomoxir significantly reduced the volume of HCTR xenograft tumors. PMC10646284
Mice OVA and HDM-induced asthma models Intraperitoneal injection 50 mg/Kg 30 minutes after and 24 hours later Etomoxir significantly reduced OVA-induced airway hyperresponsiveness, decreased the number of inflammatory cells, and reduced the production of cytokines and chemokines associated with asthma. PMC5578913
C57BL/6 mice LPS-induced peritonitis model intraperitoneal injection 100 μg Single injection, samples collected after 6 hours Etomoxir significantly increased the levels of many oxylipins during inflammation PMC8748967
BALB/c nude mice Cervical cancer lymph node metastasis model Subcutaneous injection 40 mg/kg Daily for 7 days Inhibited CPT1A activity, significantly reduced lymph node metastasis PMC11151054
mice OT-I TRM cell model intradermal injection 1 μg/site daily for 5 days Inhibited CPT1A activity, reducing the long-term survival of OT-I TRM cells PMC5509051
mice LCMV infection model intraperitoneal injection 20 mg/kg once before infection and once after infection Etomoxir treatment significantly reduced plasma IFN-α levels at day 3 post-infection and significantly increased LCMV viral load in the liver and spleen, indicating that the induction of FAO is critical for optimal type 1 IFN production and viral control following infection in vivo. PMC5695232

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.30mL

3.06mL

1.53mL

30.60mL

6.12mL

3.06mL

References

 

Historical Records

Categories